

---

**ROLE OF ARTIFICIAL INTELLIGENCE IN  
PHARMACOVIGILANCE: TRANSFORMING DRUG SAFETY  
MONITORING**

---

---

**Ms. Sulochana V.<sup>1\*</sup>, Mrs. Manibharathi G. I.<sup>2</sup>, Ms. Nandhini S.<sup>3</sup>, Ms. Madhumithra  
M.<sup>4</sup>, Ms. Gishmi G.<sup>5</sup>, Mr. Rathinavel G.<sup>6</sup>, Mr. Parthiban S.<sup>7</sup>.**

---

1. Lecturer, Department of Pharmacology, K S Rangasamy college of Pharmacy,  
Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.
2. Lecturer, Department of Pharmaceutical chemistry, K M College of Pharmacy, Uthangudi,  
- 625107 Tamil Nadu, India.
3. Assistant professor, Department of Pharmaceutics, K.S. Rangasamy college of Pharmacy,  
Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.
4. Assistant professor, Department of Pharmaceutical chemistry, K.S. Rangasamy college of  
Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.
5. Assistant professor, Department of Pharmaceutical chemistry, K.S. Rangasamy college of  
Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.
6. Professor & Principal, Department of Pharmaceutical chemistry, K.S. Rangasamy college  
of Pharmacy, Tiruchengode, Namakkal, 637 215, Tamil Nadu, India.
7. Associate Professor, Department of Pharmacology, K.S. Rangasamy college of Pharmacy,  
Tiruchengode, Namakkal, 637 215, Tamil Nadu, India. The Tamilnadu Dr.M.G.R Medical  
University, Chennai.

Article Received: 24 February 2026, Article Revised: 15 March 2026, Published on: 04 April 2026

**\*Corresponding Author: Ms. Sulochana V**

Lecturer, Department of Pharmacology, K S Rangasamy college of Pharmacy, Tiruchengode, Namakkal, 637 215,  
Tamil Nadu, India.

DOI: <https://doi-doi.org/101555/ijarp.1514>

**ABSTRACT**

Pharmacovigilance plays a crucial role in ensuring drug safety by detecting, assessing, and preventing adverse drug reactions (ADRs). However, traditional pharmacovigilance systems face challenges in managing the rapidly increasing volume and complexity of healthcare data. Artificial Intelligence (AI) has emerged as a transformative solution, enabling efficient

processing, analysis, and interpretation of large datasets from sources such as Individual Case Safety Reports (ICSRs), electronic health records, and social media. AI technologies, including machine learning, deep learning, and natural language processing, enhance key pharmacovigilance activities such as automated case processing, signal detection, causality assessment, and risk–benefit evaluation. These approaches improve the speed, accuracy, and scalability of drug safety monitoring while supporting proactive identification of potential risks. Despite these advantages, challenges such as data quality, regulatory uncertainty, ethical concerns, and lack of model transparency remain significant barriers to widespread adoption. Addressing these limitations is essential to ensure safe, reliable, and compliant implementation. Overall, AI holds significant potential to transform pharmacovigilance from a reactive system into a predictive and proactive model, ultimately improving patient safety and public health outcomes.

**KEYWORDS:** Artificial Intelligence, Pharmacovigilance, Adverse Drug Reactions, Machine Learning, Signal Detection, Drug Safety.

## INTRODUCTION

Pharmacovigilance is defined as the science and activities related to the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) and other drug-related problems. It plays a critical role in ensuring patient safety and maintaining the benefit–risk balance of medicines throughout their lifecycle. ADRs remain a major global healthcare concern, contributing significantly to hospital admissions and morbidity, thereby highlighting the need for robust drug safety monitoring systems <sup>(1)</sup>. Traditionally, pharmacovigilance has relied on spontaneous reporting systems, clinical trials, and manual review of individual case safety reports (ICSRs). While these methods have been fundamental in identifying safety issues, they are increasingly challenged by the exponential growth of healthcare data, including electronic health records, real-world evidence, and global safety databases. The increasing volume, velocity, and complexity of such data make conventional approaches time-consuming, labor-intensive, and sometimes inefficient in detecting early safety signals <sup>(2)</sup>. In recent years, artificial intelligence (AI) has emerged as a transformative technology in healthcare, offering innovative solutions to overcome these limitations. AI encompasses advanced computational techniques such as machine learning, deep learning, and natural language processing, which enable automated data analysis, pattern recognition, and predictive modeling. These technologies can process vast datasets

rapidly and accurately, thereby enhancing the efficiency of pharmacovigilance activities <sup>(3)</sup>. The integration of AI into pharmacovigilance has demonstrated significant potential in improving signal detection, automating case processing, and enabling proactive risk management. AI-driven models can identify hidden patterns in adverse event data, predict potential ADRs, and support causality assessment with greater precision. Furthermore, AI facilitates the use of real-world data sources, such as social media and electronic health records, allowing earlier detection of safety concerns compared to traditional methods <sup>(1)</sup>.


Despite these advancements, the adoption of AI in pharmacovigilance is still evolving. Challenges such as data quality, algorithm transparency, regulatory acceptance, and ethical considerations must be addressed to ensure reliable and safe implementation. Nevertheless, AI holds immense promise in transforming pharmacovigilance from a reactive system to a more proactive and predictive model of drug safety monitoring <sup>(2)</sup>.



**Figure 01: The future of Pharmacovigilance technology.**

## **OVERVIEW OF ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE**

Artificial Intelligence (AI) refers to computational techniques that simulate human intelligence, enabling systems to analyze data, learn patterns, and make decisions. In pharmacovigilance, AI is increasingly used to manage large volumes of safety data from sources such as Individual Case Safety Reports (ICSRs), electronic health records, and clinical trials. Traditional pharmacovigilance methods are often time-consuming and limited in handling complex datasets, whereas AI improves efficiency, automation, and accuracy in drug safety monitoring <sup>(1)</sup>.



**Figure 02: Represents the AI Technologies in Health care**

### 1. Machine Learning (ML)

Machine Learning (ML) is a core component of AI that enables systems to learn from data and improve performance without explicit programming. In pharmacovigilance, ML is widely applied for:

- Signal detection
- Adverse drug reaction (ADR) prediction
- Classification of safety reports

ML algorithms can analyze large pharmacovigilance databases and identify hidden associations between drugs and adverse events. Studies show that most AI applications in pharmacovigilance focus on **signal detection and data analysis**, demonstrating the growing importance of ML in this field <sup>(4)</sup>.

### 2. Natural Language Processing (NLP)

Natural Language Processing (NLP) enables computers to extract meaningful information from unstructured text such as:

- Clinical narratives
- Medical literature
- Social media data

In pharmacovigilance, NLP is used to automate the extraction of adverse event information from ICSRs and literature. It significantly reduces manual workload and improves

consistency in case processing. NLP is also useful for analyzing user-generated content as an additional source of safety data <sup>(5)</sup>.

### **3. Deep Learning (DL)**

Deep Learning (DL) is an advanced subset of machine learning that uses neural networks to model complex patterns in large datasets. In pharmacovigilance, DL is particularly effective for:

- Detecting rare or complex ADRs
- Pattern recognition in large datasets
- Predictive safety modeling

Recent studies highlight the increasing use of deep learning techniques in pharmacovigilance, especially for improving adverse event detection and handling high-dimensional data <sup>(6)</sup>.

### **4. Role of AI in Pharmacovigilance Systems**

AI enhances pharmacovigilance systems by:

- Processing large volumes of structured and unstructured data
- Improving signal detection accuracy
- Enabling faster and real-time safety monitoring


AI-driven systems can integrate multiple data sources and identify safety signals more efficiently than traditional methods, leading to improved drug safety surveillance <sup>(1)</sup>.

### **5. Integration with Pharmacovigilance Workflows**

AI is increasingly integrated into pharmacovigilance workflows such as:

- ICSR processing
- Signal detection and validation
- Risk management

These technologies help automate repetitive tasks, reduce human error, and enhance decision-making processes. AI also supports the transition from reactive to proactive pharmacovigilance systems <sup>(7)</sup>.



**Figure 03: Represents the flowchart of pharmacovigilance process.**

### Key Applications of AI in Pharmacovigilance

Artificial Intelligence (AI) has introduced significant transformation into pharmacovigilance by augmenting traditional practices with automation, predictive analytics and advanced data mining, enabling faster and more accurate detection of drug safety signals across diverse data sources. The core applications of AI in pharmacovigilance include automated case processing, signal detection, real-world data mining, causality assessment, and risk–benefit evaluation <sup>(2)</sup>.

### Automated Case Processing

Automated case processing in pharmacovigilance has emerged as a critical application of artificial intelligence (AI), offering the ability to extract relevant information from Individual Case Safety Reports (ICSRs) and reduce manual workload. Recent systematic reviews demonstrate that AI and machine learning methods can significantly streamline pharmacovigilance workflows, handling large volumes of safety data, identifying adverse drug events, and aiding in signal detection more efficiently than traditional manual processes <sup>(7)</sup>. Natural language processing (NLP) techniques, in particular, have been successfully applied to automatically extract free-text case details and improve triaging and prioritization of ICSRs, with models achieving high performance metrics in distinguishing report types and assisting assessors <sup>(8)</sup>. Several pilot studies have also confirmed the feasibility of using AI-based tools to support extraction and evaluation of adverse event reports, highlighting reductions in processing time and manual effort through automated data entry and validation <sup>(9)</sup>. Collectively, these findings indicate that AI-enabled automation can improve the efficiency and accuracy of case processing while reducing human workload, though

integration into routine practice continues to require robust validation and human oversight (7).

### Signal Detection

Artificial intelligence (AI) has transformed signal detection in pharmacovigilance by enabling the rapid identification of complex patterns in large adverse event datasets, surpassing the capabilities of traditional disproportionality-based methods. AI and machine learning (ML) models such as random forests, gradient boosting machines, and neural networks have demonstrated enhanced ability to detect potential safety signals by mining structured and unstructured data sources, including spontaneous reporting systems, electronic health records, and clinical narratives, resulting in improved sensitivity and earlier recognition of adverse drug reactions (ADRs) compared with conventional statistical approaches (10). Advanced deep learning and natural language processing (NLP) techniques allow extraction and interpretation of free-text information, further supporting near real-time signal generation and validation beyond traditional methods (11). Recent literature highlights that AI-driven frameworks can outperform classical disproportionality measures and improve signal detection performance metrics such as accuracy and detection speed (12). Moreover, AI's utility extends to identifying subtle ADR patterns and rare events that may remain undetected with standard methods, offering promise for earlier detection of uncommon adverse outcomes (13).

### Social Media and Real-World Data Monitoring

Artificial intelligence (AI) has increasingly been applied to monitor **social media platforms**, **patient forums**, and **online reviews** as complementary sources of real-world data for pharmacovigilance, enabling earlier recognition of ADRs that might be missed by traditional reporting systems. Social media data, such as posts on Twitter, Facebook, Reddit, and disease-focused discussion boards, contain unsolicited patient narratives on medication experiences that can be mined using natural language processing (NLP) and machine learning techniques to identify mentions of adverse drug events at scale. Reviews of this emerging field indicate that social media text mining can capture user-reported ADRs and broaden the scope of safety signal detection beyond conventional databases — although challenges such as noisy content and validation remain (14). Protocols for scoping reviews also highlight the utility of social media for identifying ADE data, and note that platforms from general networks to specialized forums offer complementary real-world evidence compared with

spontaneous report systems <sup>(15)</sup>. Empirical studies further demonstrate that automated extraction of ADEs from patient forums can reveal long-term and rare ADR patterns not well documented in registration trials, illustrating the capacity of online patient-generated data to supplement formal pharmacovigilance activities <sup>(16)</sup>. Moreover, recent reviews emphasize that advances in AI and NLP are critical in transforming unstructured social media content into actionable safety insights, framing social media analysis as a growing component of digital pharmacovigilance <sup>(17)</sup>.

### Causality Assessment

**Causality assessment** aims to determine whether a suspected adverse drug reaction (ADR) is likely caused by the drug rather than by other factors. Traditional causality evaluation often relies on expert judgment and structured scales such as the **World Health Organization-Uppsala Monitoring Centre (WHO-UMC) causality assessment system** and the **Naranjo algorithm**, which are widely used in post-marketing safety monitoring but have limitations in reproducibility and objectivity. These structured scales, while important, can vary significantly between assessors and lack universal agreement as a definitive standard for causality classification <sup>(17)</sup>.

In recent years, **AI-augmented approaches**, including **predictive machine learning models** and **Bayesian networks**, have been investigated to standardize and enhance causality assessment by learning from large datasets of case reports and reducing subjective variability. Machine learning frameworks have shown feasibility in predicting the likelihood of drug-event causal associations and improving the efficiency of case-level evaluation, while Bayesian networks provide probabilistic reasoning that combines expert-defined structure with data-driven parameters, demonstrating faster assessment times and robust performance compared with manual methods <sup>(18)</sup>.

These advancements suggest that integrating AI tools into causality assessment processes can improve **objectivity**, **efficiency**, and **scalability** in pharmacovigilance workflows, complementing traditional structured tools and expert review <sup>(1)</sup>.

### Predictive Models

Machine learning approaches can learn complex patterns from large datasets of spontaneous reports or electronic health records to support causality classification. Supervised models trained on expert-annotated causality labels have shown promise in automating parts of this evaluation and reducing human workload. For example, feature engineering and NLP-based

machine learning methods applied to the FDA Adverse Event Reporting System (FAERS) demonstrated that models could classify case reports for causality likelihood, illustrating the potential of predictive algorithms to assist in automated causality assessment tasks <sup>(20)</sup>.

Further, recent studies using k-nearest neighbors (kNN) and other similarity-based machine learning techniques have been developed specifically **to automate causality assessment**, providing early evidence that data-driven models can complement expert reviews by highlighting candidate causal relationships for further human evaluation (21).

### **Bayesian Networks**

Bayesian networks offer a probabilistic framework that combines expert knowledge with learned relationships from historical ADR data to estimate the likelihood of causal connections. An expert-defined Bayesian network developed for pharmacovigilance causality assessment demonstrated that the model achieved high recall for stronger causality categories and significantly **reduced the time to assessment** compared with global introspection, indicating faster, reproducible evaluation while maintaining validity <sup>(22)</sup>.

A recent narrative review highlighted that Bayesian methods and AI-driven probabilistic reasoning enhance traditional causality evaluation by incorporating large heterogeneous datasets and reducing subjectivity, further supporting the value of Bayesian networks in modern pharmacovigilance workflows <sup>(1)</sup>.

### **Risk Management and Benefit–Risk Assessment**

Artificial intelligence (AI) is increasingly applied in pharmacovigilance to support **risk management** and **benefit–risk assessment**, offering more efficient and data-driven approaches than traditional methods.

- **Continuous Safety Monitoring:** AI enables ongoing surveillance of multiple data sources, including spontaneous reporting systems, electronic health records, and real-world evidence. Machine learning algorithms can automatically detect emerging safety signals, track trends in adverse drug reactions (ADRs), and alert pharmacovigilance teams in near real-time. This continuous monitoring reduces the lag between signal emergence and detection compared with manual periodic reviews <sup>(23)</sup>.
- **Risk Evaluation:** AI-powered predictive models assess the likelihood, severity, and impact of potential adverse events, allowing identification of high-risk populations and drugs. Bayesian networks and machine learning classifiers can quantify risk levels by analyzing large datasets, supporting evidence-based prioritization of safety concerns (24).

- **Decision-Making Processes:** By integrating heterogeneous data from clinical trials, post-marketing reports, and real-world evidence, AI enhances regulatory and clinical decision-making. Decision support systems can recommend safety interventions, label modifications, or targeted risk minimization strategies, improving the timeliness and accuracy of benefit–risk assessments <sup>(25)</sup>.

### **Technologies Used in AI-Based Pharmacovigilance**

Modern pharmacovigilance increasingly relies on advanced computational technologies to handle large and complex datasets generated from spontaneous reporting systems, clinical records, literature, and real-world sources. **Machine learning (ML) algorithms** — including random forests, support vector machines, and other classifiers — have been widely applied to detect patterns, classify adverse drug reactions (ADRs), and support safety signal detection by learning from historical pharmacovigilance data. This widespread use of ML in pharmacovigilance has been documented in systematic reviews that highlight its potential across multiple stages of drug safety monitoring <sup>(4)</sup>.

In addition to conventional ML, **deep learning models** such as convolutional neural networks (CNNs) and transformer-based architectures have shown improved performance in extracting complex features from both structured and unstructured data — particularly in clinical text mining and ADR detection — outperforming traditional models on benchmark datasets <sup>(11)</sup>.

A key supporting technology is **Natural Language Processing (NLP)**, which enables automated interpretation and extraction of relevant pharmacovigilance information from free-text sources such as electronic health records (EHRs), literature, social media, and patient-generated content. Structured reviews specifically describe how NLP techniques have advanced ADE detection from unstructured clinical narratives and facilitated real-world signal detection <sup>(5)</sup>.

Finally, **Big Data analytics** — the integration and analysis of massive heterogeneous datasets — complements AI methods by enabling scalable processing and advanced modeling of multidimensional safety data. With growing volumes of pharmacovigilance data from diverse sources, big data frameworks support the efficient extraction of patterns that inform risk management and regulatory decision-making <sup>(26)</sup>.

### **Advantages of AI in Pharmacovigilance**

Artificial intelligence (AI) is rapidly transforming pharmacovigilance (PV) by addressing key limitations of traditional safety monitoring systems and improving the handling of

ever-growing pharmacovigilance data volumes. Overall, AI significantly enhances **efficiency, accuracy, timeliness, and resource utilization** in drug safety monitoring.

• **Faster Data Processing:**

AI-powered systems can process and analyze large datasets — including spontaneous reports, clinical records, and real-world evidence — more rapidly than manual methods. By automating routine tasks (e.g., duplicate detection, case intake and triage), AI reduces the time between data receipt and actionable safety insights, accelerating pharmacovigilance workflows. This speedup in processing is one of the core benefits highlighted across systematic reviews of AI in PV <sup>(7)</sup>.

• **Improved Accuracy:**

Machine learning (ML), deep learning, and natural language processing models improve the identification of adverse drug events and safety signals by uncovering patterns not easily detected by human reviewers or conventional statistical methods. Enhanced accuracy has been repeatedly documented, particularly in text-based adverse event detection tasks using benchmark datasets and real clinical narratives <sup>(6)</sup>.

• **Early Signal Detection:**

AI can continuously monitor incoming data streams and flag emerging trends before they become apparent in traditional signal detection approaches. This capability is especially valuable for identifying previously unreported or rare adverse drug reactions, enabling more proactive safety management. Narrative and systematic reviews emphasize AI's role in early signal detection across diverse data sources <sup>(1)</sup>.

• **Reduced Manual Workload:**

By automating repetitive and labor-intensive tasks such as case processing, data extraction, and preliminary safety assessment, AI reduces the burden on human pharmacovigilance professionals. This allows experts to focus on complex interpretation, decision-making, and regulatory responses rather than routine data handling <sup>(27)</sup>.

• **Long-Term Cost-Effectiveness:**

Although upfront investment in AI infrastructure and model development can be substantial, the long-term benefits include reduced personnel costs, fewer delays in safety evaluation, and more efficient resource allocation. AI's ability to scale with growing data volumes — without

proportional increases in human effort — suggests cost advantages over time in pharmacovigilance operations. While specific PV cost-effectiveness studies are limited, broader reviews of AI in healthcare demonstrate that AI applications often yield economic benefits by optimizing workflows and reducing unnecessary processes (28).

Collectively, these advantages indicate that AI enhances the capacity of pharmacovigilance systems to manage complex, high-volume data more efficiently and accurately than traditional methods, contributing to improve drug safety monitoring and earlier identification of potential risks to patients.

**Table no: 1 Comparison of traditional vs. AI-driven approaches in healthcare.**

Aspect	Traditional Approach	AI-Driven Approach
Speed	Slower data processing and analysis, relying on manual review.	Faster processing along with analysis, real-time data handling.
Accuracy	Subject to human error and leaning in diagnosis.	Increased accuracy through machine learning algorithms.
Scalability	Finite by resources, labor-intensive for large datasets.	Highly scalable, skilled to handle vast amounts of data.
Data Handling	Handbook collection and analysis of patient data.	Automates data extraction, integration, and analysis.
Decision-Making	Decisions may be slower due to dependence on clinical judgment.	AI models aid in faster decision-making with evidence-based predictions.
Cost Efficiency	Higher due to manual labor, slower processes, and longer wait times.	Can lower costs by automating processes and improving efficiency.

### Challenges and Limitations of AI in Pharmacovigilance

While artificial intelligence (AI) holds significant promise for advancing pharmacovigilance, several key challenges and limitations must be addressed to ensure its effective and responsible adoption.

#### Data Quality Issues

AI models require high-quality and representative data to perform reliably. In pharmacovigilance, datasets such as spontaneous reporting systems, electronic health records, and patient-generated narratives often contain **missing fields, inconsistent terminology, and unstructured text**, which can degrade model performance, introduce noise, and lead to biased or inaccurate predictions. These **data quality issues** are recognized as a fundamental barrier to reliable AI implementation in drug safety monitoring (29).

#### Privacy and Ethical Concerns

The use of patient data — including demographics, clinical histories, and adverse event details — raises important **privacy and ethical concerns**. AI systems processing sensitive

health information must ensure confidentiality, proper consent, and data protection to maintain public trust and comply with ethical standards. Failing to do so risks data breaches, re-identification of anonymized data, and erosion of patient autonomy. Ethical analysis of AI in healthcare highlights these challenges and emphasizes the need for robust governance frameworks to protect patient rights <sup>(30)</sup>.

### **Regulatory Challenges**

Clear and consistent regulatory guidelines for implementing AI in pharmacovigilance are still evolving. Regulatory bodies are working to define standards for validation, transparency, and risk management of AI systems, but **global consensus and practical frameworks** remain limited. This uncertainty can hinder AI adoption, slow approval processes, and complicate compliance for organizations trying to align AI tools with regulatory expectations. Recent regulatory-focused reviews stress the importance of explainability and oversight mechanisms in pharmacovigilance applications <sup>(31)</sup>.

### **Interpretability (Black Box Problem)**

Many AI models — particularly deep learning systems — function as “black boxes,” producing predictions without easily interpretable reasoning. This **lack of interpretability** presents challenges for pharmacovigilance experts who must understand and justify decisions related to adverse event detection, causality assessment, and risk management. The “black box problem” can reduce trust among clinicians, regulators, and stakeholders and limits the integration of AI into formal decision-making processes. Research on explainable AI (XAI) underscores the need for methods that make AI outputs transparent and auditable <sup>(31)</sup>.

### **Regulatory Perspective**

Regulatory authorities worldwide are increasingly exploring the integration of artificial intelligence (AI) into pharmacovigilance systems as part of efforts to enhance drug safety monitoring. However, this transition raises important **validation** and **compliance** considerations that must be addressed to ensure AI is safe, effective, and acceptable within regulated environments.

### **Validation of AI Models is required**

Regulatory guidelines for pharmacovigilance emphasize that technologies used in safety monitoring — including artificial intelligence (AI) and machine learning (ML) systems — must be **validated to demonstrate fitness for purpose, reliability, and consistent performance** before they can be trusted for high-stakes decisions such as adverse event detection or signal prioritization. A structured validation process ensures that AI models

function as intended across diverse datasets and under varying conditions, with documented evidence of performance and robustness that meets regulatory expectations. Existing literature on intelligent automation in pharmacovigilance highlights that traditional validation frameworks can be **extended with tailored activities** to verify AI-based systems, such as defining performance thresholds, risk assessment of model deployment, and lifecycle validation steps to demonstrate a system's reliability and compliance with regulatory requirements <sup>(32)</sup>.

Moreover, pharmacovigilance compliance frameworks specify that **AI and ML implementations must be assessed proportionate to the potential risk to patient safety**, including documentation of risk control plans, quality management oversight, and inspection readiness. Systems must be demonstrated as **fit-for-use through formal validation protocols** that evaluate data selection, model training, testing, and ongoing performance monitoring — all of which are essential components of regulatory clearance or inspection readiness in highly regulated PV environments <sup>(33)</sup>.

Together, these sources illustrate that the validation of AI models in pharmacovigilance isn't merely a technical exercise but a **regulatory imperative** that ensures their **fitness for regulatory use, traceability of decisions, and consistent performance**, laying the foundation for broader acceptance and compliant implementation in drug safety systems <sup>(34)</sup>.

### **Compliance with Guidelines is Essential**

Compliance with both **established and emerging regulatory guidelines** is essential for safe and effective AI adoption in pharmacovigilance, as regulators increasingly scrutinize how AI systems are integrated into drug safety workflows. Regulatory authorities such as the **U.S. Food and Drug Administration (FDA)** and international bodies recognise the potential of AI but emphasise that these systems must align with current pharmacovigilance standards, including adherence to **data integrity, audit readiness, and quality system requirements** to maintain trust and compliance in safety monitoring activities. For example, regulatory discussions on explainability underscore that AI algorithms should offer transparent and interpretable outputs so that decisions related to ADR detection and signal prioritization can be justified and documented in accordance with regulatory expectations <sup>(35)</sup>.

Moreover, compliance frameworks being explored by regulators highlight the need for **governance structures** that oversee the lifecycle of AI/ML tools in pharmacovigilance, including accountability for data quality, monitoring, and third-party technologies. Editorials and reviews in the pharmacovigilance regulatory literature stress that governance mechanisms are necessary to ensure that AI systems remain within the scope of regulatory

requirements and that their outputs can be audited and traced back during inspections or regulatory submissions <sup>(36)</sup>.

Overall, while regulatory authorities continue to recognise the benefits of AI for enhancing pharmacovigilance, they **underscore rigorous compliance with evolving guidelines**, emphasizing explainability, documentation, and governance to ensure safety, transparency, and regulatory acceptance. As guidance continues to evolve, robust **documentation practices, transparent methodologies**, and evidence of compliance will be essential to integrating AI into routine pharmacovigilance practice and fulfilling regulatory obligations <sup>(35)</sup>.

### **Future Perspectives of AI in Pharmacovigilance**

Artificial intelligence (AI) is expected to become a core component of pharmacovigilance workflows, driving **fully automated systems, real-time adverse drug reaction (ADR) monitoring, integration with electronic health records (EHRs), predictive safety analytics**, and **personalized medicine**. Emerging research highlights how AI is moving pharmacovigilance from retrospective analysis to proactive, continuous safety surveillance. Future pharmacovigilance systems are envisioned as fully automated, capable of processing vast quantities of multisource data—from spontaneous reports to clinical records—without extensive manual intervention, thus accelerating safety signal generation <sup>(12)</sup>.

Real-time monitoring of ADRs is being enabled by advanced AI methods such as deep learning and natural language processing, which can integrate unstructured clinical notes with structured data streams to detect safety signals with minimal delay and enhance responsiveness in post-market surveillance <sup>(12)</sup>. Integration with EHRs and other digital health data sources is increasingly recognized as a crucial future direction, as EHR-based surveillance complements spontaneous reporting systems and captures a broader spectrum of patient experiences in routine care <sup>(37)</sup>.

Predictive safety analytics powered by machine learning models promise to anticipate ADRs and identify patient subgroups at higher risk, supporting proactive risk management and earlier interventions. These predictive capabilities extend into personalized medicine, where AI models use patient-specific variables and real-world data to tailor safety profiles and potentially personalize drug selection and dosing to optimize outcomes and minimize harm <sup>(7)</sup>.

Taken together, these future perspectives indicate that AI will transform pharmacovigilance into a predictive, integrated, and patient-centered discipline, ultimately enhancing drug safety and public health outcomes.

**Table No 02: Examples of AI Applications in Pharmacovigilance.**

AI Application	Description	Real-World Example
<b>Adverse Event Detection</b>	AI systems evaluated large datasets, including social media and EHRs, to identify potential adverse drug reactions.	IBM Watson Health uses AI to detect adverse events from electronic health records.
<b>Predictive Modeling</b>	AI anticipate the likelihood of adverse events based on patient demographics, drug interactions, and usage patterns.	AstraZeneca employs machine learning to predict drug safety risks during development.
<b>Signal Detection Tools</b>	AI algorithms identify signals of potential safety concerns by processing pharmacovigilance databases.	FDA Sentinel System uses AI to enhance signal detection in pharmacovigilance.
<b>Natural Language Processing (NLP)</b>	NLP extracts adverse event reports from unstructured data, such as clinical notes or social media posts.	BioPharm Solutions leverages NLP to analyse social media for drug safety insights.
<b>Automation of Reporting</b>	AI automates the creation and submission of regulatory safety reports to streamline compliance.	Aris Global's Life Sphere automates case processing and regulatory reporting tasks.
<b>Risk-Benefit Analysis</b>	AI assesses drug safety profiles by balancing risks and benefits across patient populations.	Bayer uses AI-driven platforms for comprehensive drug safety evaluation

## CONCLUSION

Artificial Intelligence is reshaping pharmacovigilance by enhancing the efficiency, accuracy, and timeliness of drug safety monitoring. Through advanced techniques such as machine learning, deep learning, and natural language processing, AI enables automated case processing, improved signal detection, and more objective causality assessment. The integration of AI with real-world data sources further strengthens the ability to detect adverse drug reactions early and manage risks proactively.

However, the successful implementation of AI in pharmacovigilance requires overcoming key challenges, including data quality issues, ethical and privacy concerns, regulatory uncertainties, and the need for model transparency. Robust validation, regulatory compliance, and governance frameworks are essential to ensure trust and reliability in AI-driven systems.

Looking forward, AI is expected to play a central role in developing fully automated, real-time, and predictive pharmacovigilance systems. With continued advancements and appropriate regulatory support, AI has the potential to significantly improve drug safety surveillance, optimize benefit–risk assessment, and ultimately enhance patient care and public health.

## REFERENCES

1. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. *Int J Clin Pharm*. 2025 Aug; 47(4):932-944. doi: 10.1007/s11096-025-01975-3. Epub 2025 Jul 30. PMID: 40736603; PMCID: PMC12335403.
2. Nagar A, Gobburu J, Chakravarty A. Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration. *Ther Adv Drug Saf*. 2025 Jul 31; 16:20420986251361435. doi: 10.1177/20420986251361435. PMID: 40756610; PMCID: PMC12317250.
3. Aronson JK. Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations. *Drug Saf*. 2022 May; 45(5):407-418. doi: 10.1007/s40264-022-01156-5. Epub 2022 May 17. PMID: 35579806.
4. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M, Bain PA, Woloszynek S, Painter JL, Bate A, Beam AL. Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review. *Drug Saf*. 2022 May; 45(5):477-491. doi: 10.1007/s40264-022-01176-1. Epub 2022 May 17. Erratum in: *Drug Saf*. 2023 Apr; 46(4):433. doi: 10.1007/s40264-023-01273-9. PMID: 35579812; PMCID: PMC9883349.
5. Pilipiec P, Liwicki M, Bota A. Using Machine Learning for Pharmacovigilance: A Systematic Review. *Pharmaceutics*. 2022 Jan 23; 14(2):266. doi: 10.3390/pharmaceutics14020266. PMID: 35213998; PMCID: PMC8924891.
6. Li Y, Tao W, Li Z, Sun Z, Li F, Fenton S, Xu H, Tao C. Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. *J Biomed Inform*. 2024 Apr; 152:104621. doi: 10.1016/j.jbi.2024.104621. Epub 2024 Mar 5. PMID: 38447600.
7. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, Junaid T, Bostic T. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. *Pharmaceut Med*. 2022 Oct;36(5):295-306. doi: 10.1007/s40290-022-00441-z. Epub 2022 Jul 29. PMID: 35904529.
8. Lieber T, Gosselt HR, Kools PC, Kruijssen OC, Van Lierop SNC, Härmark L, Van Hunsel FPAM. Natural language processing for automated triage and prioritization of individual case safety reports for case-by-case assessment. *Front Drug Saf Regul*. 2023 Feb 7; 3:1120135. doi: 10.3389/fdsfr.2023.1120135. PMID: 40980103; PMCID: PMC12443081.

9. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing. *Clin Pharmacol Ther.* 2019 Apr; 105(4):954-961. doi: 10.1002/cpt.1255. Epub 2018 Dec 11. PMID: 30303528; PMCID: PMC6590385.
10. Warner J, Prada Jardim A, Albera C. Artificial Intelligence: Applications in Pharmacovigilance Signal Management. *Pharmaceut Med.* 2025 May; 39(3):183-198. doi: 10.1007/s40290-025-00561-2. Epub 2025 Apr 21. PMID: 40257538; PMCID: PMC12126317.
11. Khemani DB, Malave DS, Shinde S, Shukla M, Shikalgar R, Talwar H. AI-driven pharmacovigilance: Enhancing adverse drug reaction detection with deep learning and NLP. *MethodsX.* 2025 Jun 23; 15:103460. doi: 10.1016/j.mex.2025.103460. PMID: 40678458; PMCID: PMC12268696.
12. Ali U, Batool ST, Mahato RK. Artificial intelligence in pharmacovigilance: toward real-time, explainable, and global drug-safety systems. *Ann Med Surg (Lond).* 2026 Jan 20; 88(2):2196-2197. doi: 10.1097/MS9.0000000000004699. PMID: 41675893; PMCID: PMC12889357.
13. Jain A, Adenwala Z. The role of artificial intelligence in pharmacovigilance for rare diseases. *Expert Opin Drug Saf.* 2025 Aug;24(8):893-898. doi: 10.1080/14740338.2025.2474645. Epub 2025 Mar 3. PMID: 40022540.
14. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G. Utilizing social media data for pharmacovigilance: A review. *J Biomed Inform.* 2015 Apr;54:202-12. doi: 10.1016/j.jbi.2015.02.004. Epub 2015 Feb 23. PMID: 25720841; PMCID: PMC4408239.
15. Golder S, O'Connor K, Wang Y, Gonzalez Hernandez G. The Role of Social Media for Identifying Adverse Drug Events Data in Pharmacovigilance: Protocol for a Scoping Review. *JMIR Res Protoc.* 2023 Aug 2;12:e47068. doi: 10.2196/47068. PMID: 37531158; PMCID: PMC10433020.
16. Dirkson A, Verberne S, Kraaij W, van Oortmerssen G, Gelderblom H. Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers. *Sci Rep.* 2022 Jun 20;12(1):10317. doi: 10.1038/s41598-022-13894-8. PMID: 35725736; PMCID: PMC9209513.
17. Dong F, Guo W, Liu J, Patterson TA, Hong H. Pharmacovigilance in the digital age: gaining insight from social media data. *Exp Biol Med (Maywood).* 2025 May

- 27;250:10555. doi: 10.3389/ebm.2025.10555. PMID: 40495881; PMCID: PMC12149966.
18. Manjhi PK, Singh MP, Kumar M. Causality, Severity, Preventability and Predictability Assessments Scales for Adverse Drug Reactions: A Review. *Cureus*. 2024 May 9;16(5):e59975. doi: 10.7759/cureus.59975. PMID: 38854273; PMCID: PMC11162198.
  19. Rodrigues PP, Ferreira-Santos D, Silva A, Polónia J, Ribeiro-Vaz I. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network. *Artif Intell Med*. 2018 Sep;91:12-22. doi: 10.1016/j.artmed.2018.07.005. Epub 2018 Aug 2. PMID: 30077492.
  20. Kreimeyer K, Dang O, Spiker J, Muñoz MA, Rosner G, Ball R, Botsis T. Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System. *Comput Biol Med*. 2021 Aug;135:104517. doi: 10.1016/j.combiomed.2021.104517. Epub 2021 Jun 8. PMID: 34130003.
  21. Ren, J., Carroll, H., McCarthy, K. *et al.* A kNN based machine learning approach to automating causality assessment of adverse events. *Sci Rep* **16**, 9140 (2026). <https://doi.org/10.1038/s41598-026-40267-2>
  22. Rodrigues PP, Ferreira-Santos D, Silva A, Polónia J, Ribeiro-Vaz I. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network. *Artif Intell Med*. 2018 Sep;91:12-22. doi: 10.1016/j.artmed.2018.07.005. Epub 2018 Aug 2. PMID: 30077492.
  23. Diao W, Yang B, Sun S, Wang A, Kou R, Ge Q, Shi M, Lian B, Sun T, Wu J, Bai J, Qu M, Wang Y, Yu W, Gao Z. PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer. *Front Pharmacol*. 2022 Jun 15;13:893151. doi: 10.3389/fphar.2022.893151. PMID: 35784721; PMCID: PMC9240350.
  24. Shohat S, Vol E, Shifman S. Gene essentiality in cancer cell lines is modified by the sex chromosomes. *Genome Res*. 2022 Nov-Dec;32(11-12):1993-2002. doi: 10.1101/gr.276488.121. Epub 2022 Nov 23. PMID: 36418059; PMCID: PMC9808629.
  25. Kolmangadi MA, Wani YM, Schönhals A, Nikoubashman A. Coarse-Grained Simulations of Columnar Ionic Liquid Crystals: Comparison with Experiments. *J Phys Chem B*. 2024 Aug 29;128(34):8215-8222. doi: 10.1021/acs.jpcc.4c03041. Epub 2024 Aug 20. PMID: 39163525.

26. Hussain, R. Big data, medicines safety and pharmacovigilance. *J of Pharm Policy and Pract* **14**, 48 (2021). <https://doi.org/10.1186/s40545-021-00329-4>
27. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. *Indian J Pharmacol.* 2019 Nov-Dec;51(6):373-376. doi: 10.4103/ijp.IJP\_814\_19. Epub 2020 Jan 16. PMID: 32029958; PMCID: PMC6984023.
28. El Arab, R.A., Al Moosa, O.A. Systematic review of cost effectiveness and budget impact of artificial intelligence in healthcare. *npj Digit. Med.* **8**, 548 (2025). <https://doi.org/10.1038/s41746-025-01722-y>
29. Desai MK. Artificial intelligence in pharmacovigilance - Opportunities and challenges. *Perspect Clin Res.* 2024 Jul-Sep;15(3):116-121. doi: 10.4103/picr.picr\_290\_23. Epub 2024 Mar 27. PMID: 39140015; PMCID: PMC11318788.
30. Jain A, Salas M, Aimer O, Adenwala Z. Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance. *Drug Saf.* 2025 Feb;48(2):119-127. doi: 10.1007/s40264-024-01483-9. Epub 2024 Sep 27. PMID: 39331228.
31. Ali U, Batool ST, Mahato RK. Artificial intelligence in pharmacovigilance: toward real-time, explainable, and global drug-safety systems. *Ann Med Surg (Lond).* 2026 Jan 20;88(2):2196-2197. doi: 10.1097/MS9.0000000000004699. PMID: 41675893; PMCID: PMC12889357.
32. Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, Leonard E, Taylor R, Patel B, Abatemarco D. Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices. *Drug Saf.* 2021 Mar;44(3):261-272. doi: 10.1007/s40264-020-01030-2. Epub 2021 Feb 1. PMID: 33523400; PMCID: PMC7892696.
33. Glaser M, Littlebury R. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed? *Ther Adv Drug Saf.* 2024 Oct 31;15:20420986241293303. doi: 10.1177/20420986241293303. PMID: 39493927; PMCID: PMC11528645.
34. Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, Leonard E, Taylor R, Patel B, Abatemarco D. Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices. *Drug Saf.* 2021 Mar; 44(3):261-272. doi: 10.1007/s40264-020-01030-2. Epub 2021 Feb 1. PMID: 33523400; PMCID: PMC7892696.

35. Pinheiro LC, Kurz X. Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability. *Pharmacoepidemiol Drug Saf.* 2022 Dec; 31(12):1308-1310. doi: 10.1002/pds.5524. Epub 2022 Sep 8. PMID: 35959980.
36. Glaser M, Littlebury R. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed? *Ther Adv Drug Saf.* 2024 Oct 31;15:20420986241293303. doi: 10.1177/20420986241293303. PMID: 39493927; PMCID: PMC11528645.
37. Edrees H, Song W, Syrowatka A, Simona A, Amato MG, Bates DW. Intelligent Telehealth in Pharmacovigilance: A Future Perspective. *Drug Saf.* 2022 May;45(5):449-458. doi: 10.1007/s40264-022-01172-5. Epub 2022 May 17. PMID: 35579810; PMCID: PMC9112241.